Maxim Group analyst Caroline Palomeque maintained a Buy rating on Daré Bioscience Inc (DARE) today and set a price target of $3. The company’s shares opened today at $1.31.
Palomeque commented:
“Daré Bioscience announced that is has acquired the global rights to MP-101 for the treatment of bacterial vaginosis (BV) from Hammock Pharmaceuticals (private), TriLogic Pharma (private) and MilanaPharm (private). In addition, Daré will have the rights to the in-situ hydrogel drug delivery technology for any vaginal or urological indication.”
According to TipRanks.com, Palomeque ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -14.8% and a 23.2% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.
Daré Bioscience Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.59 and a one-year low of $0.74. Currently, Daré Bioscience Inc has an average volume of 104.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Daré Bioscience, Inc. operates as a healthcare company. It engages in the development and commercialization of pharmaceutical products in women’s reproductive health. Its products inclide Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert, and Roger L. Hawley in 2015 and is headquartered in La Jolla, CA.
